A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: TImes Now
Hyderabad-based paediatrician Dr Sivaranjani Santosh has once again demonstrated how a doctor's efforts can extend beyond the clinic. Widely known as the "ORS Lady of India" for her eight-year campaign against sugary beverages falsely marketed as oral rehydration solutions (ORS), she has now helped make a rare disease medicine significantly more affordable.
Through her efforts and collaboration with international organisations, the estimated annual cost of tiratricol treatment for children with Allan-Herndon-Dudley syndrome (AHDS) has fallen from ₹9 crore to approximately ₹2.5 lakh per child.
AHDS, also known as monocarboxylate transporter 8 (MCT8) deficiency, is a rare X-linked genetic disorder that disrupts brain development and movement, primarily affecting males. It is caused by mutations in the SLC16A2 gene, which encodes the protein responsible for transporting thyroid hormones into brain cells.
Seven children with the condition are set to receive a year's supply of tiratricol free of cost on November 30.
"Feeling so relieved! It had been a roller coaster ride!" Dr Sivaranjani shared in a post on X.
The initiative began after Arav, a child under Dr Sivaranjani's care, was diagnosed with AHDS. His mother, Pavitra, was paying approximately ₹12 lakh to ₹13 lakh for a month's supply of the medicine from Germany.
Although tiratricol was available in Europe, its commercial price made it unaffordable for most families. A compounded formulation prepared by Netherlands-based Transvaal Pharmacy is estimated to cost just ₹2.5 lakh per child for a year.
Tiratricol, also known as TRIAC, is a thyroid hormone analogue that helps address hormonal imbalances associated with MCT8 deficiency and reduce complications linked to excess thyroid hormone activity in peripheral tissues.
Transvaal Pharmacy prepared the formulation with support from the Netherlands-based Pharmaceutical Accountability Foundation (PAF).
The medicine has reached India through the appropriate channels and with the necessary permissions. It will be handed over to the seven families, who have secured approvals for one year of treatment.
"Parents of those children I am a paediatrician for donated generously, and Pharmaceutical Accountability Foundation raised funds too. So, the parents of these seven children didn't have to pay a single rupee for the medicine," Dr Sivaranjani said.
As the medicine has a six-month shelf life, it will be imported in two batches, The Hindu reported.
Read More: Rare Diseases Day: How AI Is Transforming Early Diagnosis
According to PAF, providing one year's treatment to all seven children will cost €14,200, approximately ₹15.08 lakh.
Dr Sivaranjani raised approximately ₹6.09 lakh in India, while PAF undertook to raise the remaining €8,600, approximately ₹9.13 lakh, in the Netherlands.
The contributions will ensure that all seven families receive the medicine free of cost.
Attempts to access tiratricol through Egetis Therapeutics' compassionate-use programme failed. On September 7, Dr Sivaranjani appealed for help on social media, bringing the case to the attention of PAF. The foundation then worked with Transvaal Pharmacy to develop a compounded formulation using the active pharmaceutical ingredient for the seven children.
Calling the situation an example of "pharma piracy", Dr Sivaranjani questioned why a medicine that could be compounded for approximately ₹2.5 lakh was being made inaccessible to families through commercial
pricing of around ₹9 crore.
Dr Sivaranjani has urged the Indian government to enable domestic compounding of the active pharmaceutical ingredient (API) and make the medicine available under the National Policy for Rare Diseases. "We can easily prepare it here, and it would cost even less," she said.
Credit: AI
As the United States lost its measles elimination status of more than 25 years, Health and Human Services Secretary Robert F. Kennedy Jr. and his long record of challenging established public health norms and policies are being heavily scrutinised.
The US has reported more than 5,700 measles infections and 11 deaths in 2026, amid an alarming decline in childhood vaccination coverage in several states.
A recent Reuters investigation examined how vaccine skepticism and gaps in outbreak response have contributed to the country's measles crisis.
Kennedy, a longtime vaccine skeptic, had made several controversial health claims about several things like removing fluoride in drinking water, promoting raw milk, linking tylenol and autism, COVID-19 and cellphone radiation.Some of his concerns relate to legitimate areas of scientific debate but many others clash with established evidence.
Vaccine-autism controversy dates back to a 1998 study which suggested a link between the MMR vaccine and autism. The paper was subsequently retracted.But Kennedy has been a long-time skeptic of vaccines, questioning their efficacy and safety on multiple occasions.
He has repeatedly argued that vaccines can contribute to autism as their ingredients and childhood immunisation schedules have not been adequately studied.
But extensive research has found no relationship between vaccines and autism. A World Health Organization review published in September 2026 examined studies published between 2010 and August 2025 and defied this claim.
Also read: World Immunization Day: Former CDC Advisor Explains Why The Vaccine-Autism Myth Is So Hard To Debunk
Kennedy has also questioned the safety of the combined measles, mumps and rubella (MMR) vaccine, supporting President Trump's proposal to separate the three vaccines.
In August 2026, he defended an executive order calling to pursue the option of separating the combination vaccine. He also cited research that he said supported the move.
However, vaccine experts have said there is no evidence that splitting the MMR vaccine makes it safer or reduces autism risk. In fact, they said that separating the shots could also mean more injections and delays in completing vaccination, leaving children vulnerable to infection.
Kennedy has advocated for raw, unpasteurised milk, claiming it is healthier than pasteurised milk and that it is better for gut health. However, the US Food and Drug Administration (FDA) says these benefits have not been scientifically backed.
Pasteurisation involves heating milk to eliminate harmful microorganisms. Raw milk can carry pathogens like E. coli, Salmonella, Listeria and Campylobacter, which can cause serious foodborne illness.
The FDA has documented outbreaks due to contaminated raw milk, including illnesses involving kidney failure and pregnancy complications.
Kennedy has called fluoride an industrial waste product and pushed for its removal from public water supplies.
There is a legitimate scientific discussion about fluoride exposure at high levels. A US National Toxicology Program review found that higher fluoride exposures, especially those above recommended drinking-water levels, were linked to lower IQ scores in children.
But it does not prove that fluoride at the levels used in community water fluoridation produces the same effects.
The US Centers for Disease Control and Prevention (CDC) continues to support community water fluoridation at the recommended concentration of 0.7 milligrams per litre. It considers this an effective way to prevent tooth decay.
During the COVID-19 pandemic, Kennedy argued that more use of ivermectin and hydroxychloroquine could have reduced deaths. But subsequent clinical trials and systematic reviews did not establish that either drug improved any outcome for people with COVID-19.
A 2025 systematic review and network meta-analysis published in the BMJ, covering hundreds of trials, found that neither ivermectin nor hydroxychloroquine reduced hospital admissions or mortality compared to routine treatments in people with COVID-19.
Kennedy has also spoken against acetaminophen, sold under the brand name Tylenol, and its role in autism risk when used during pregnancy.
It attracted scientific attention as some studies observed links between prenatal acetaminophen exposure and neurodevelopmental conditions. But evidence is still inconclusive.
In September 2025, the FDA acknowledged that evidence suggesting a possible link but explicitly stated that it had not been established thoroughly.
Kennedy has also claimed that circumcision can cause autism, which is, too, not supported by science.
As part of his Make America Healthy Again agenda, Kennedy criticised seed oils, including soybean, corn, canola and sunflower oils, suggesting that they cause inflammation and chronic disease. He also promoted alternatives like beef tallow.
But evidence does not support that seed oils are inherently harmful. These oils contain unsaturated fats and replacing saturated fats with polyunsaturated fats can help lower LDL cholesterol, which is a risk factor for cardiovascular disease.
The American Heart Association's 2026 dietary guidance supports replacing sources of saturated fat, including butter and beef tallow, with oils rich in unsaturated fats.
Kennedy has warned that electromagnetic radiation from wireless devices could damage mitochondria, disrupt biological processes and increase cancer risk.
Cellphones emit radiofrequency radiation, which is non-ionising and does not have enough energy to directly damage DNA in the way that ionising radiation, like X-rays, can.
The US National Cancer Institute says that evidence to date suggests cellphone use does not cause brain or other cancers in humans.
Kennedy has repeatedly questioned whether childhood vaccines have been tested for safety sufficiently, arguing that many have not been evaluated in placebo-controlled trials. This claim can be misleading as it deems only one type of trial as acceptable and safe.
Vaccines undergo clinical testing before approval. Their safety and effectiveness are evaluated through different study designs. Depending on the vaccine, trials may compare a new vaccine with an existing vaccine or another appropriate control rather than a placebo.
In a 2021 interview, Kennedy suggested that Black Americans should follow a different vaccination schedule from white Americans, claiming that Black people had stronger immune systems and could be more vulnerable to vaccine’s side effects.
Medical experts defied the argument as scientifically unreliable. There is no established basis for assigning vaccination schedules according to race.
Vaccine recommendations are based on factors like age, medical history, immune status, exposure risk and other clinical considerations.
Credit: Mark Kelly/X
Actress Olivia Munn has joined US Senator Mark Kelly to push for legislation that would make breast cancer risk assessments a routine part of healthcare for American women, helping them understand their individual risk and access appropriate screening.
Together, they have introduced the Know Your Risk Act, which aims to expand access to validated breast cancer risk assessment tools and integrate them into routine healthcare.
Munn, who was diagnosed with breast cancer in 2023, said a risk assessment prompted her doctor to recommend further testing despite her having a normal mammogram and negative genetic testing. The additional tests detected an aggressive cancer early.
"Had it not been for that assessment, my breast cancer may not have been identified when it was," Munn said while announcing the legislation alongside Kelly.
Also read: World Breast Cancer Day 2026: Life After Breast Cancer, The Fear No One Sees
Announcing the legislation outside the US Capitol, Kelly said existing breast cancer risk assessment tools are not being used widely enough, leaving many women unaware of their individual risk.
"These tools already exist, but too often doctors aren't using them and women don't know that they're available," Kelly said.
The Democratic senator from Arizona said the Act would make breast cancer risk assessments a routine part of healthcare, helping women and their doctors understand individual risk and determine appropriate screening.
"Women shouldn't have to ask for these assessments. They should be part of regular care like getting a blood pressure reading taken," Kelly said.
He added that the legislation had bipartisan support, with lawmakers recognizing the importance of expanding access to early detection.
Munn's experience highlights why individual risk assessments matter, particularly when standard screening and genetic testing may not identify a woman's breast cancer risk.
Despite having a normal mammogram and negative genetic testing, her risk assessment prompted further investigations that led to her diagnosis.
She said the experience motivated her to work with Kelly to ensure other women have access to similar assessments.
According to the World Health Organization (WHO), breast cancer caused an estimated 694,000 deaths worldwide in 2024. It was the most commonly diagnosed cancer among women in 164 of 186 countries.
In the US, breast cancer is the second leading cause of cancer death among women, according to the Centers for Disease Control and Prevention (CDC).
Early detection can significantly improve breast cancer outcomes. According to the National Cancer Institute, the five-year relative survival rate for women with localized breast cancer is more than 99%.
During the announcement, a representative of breast cancer organization Susan G. Komen highlighted the difference between detecting the disease before and after it spreads, noting that survival rates can fall to around 30% when breast cancer is diagnosed at a distant stage.
The representative also pointed to the rising number of diagnoses among women under 50, many of whom may not consider themselves at risk.
The Know Your Risk Act seeks to address this gap by expanding access to validated risk assessment tools, helping women and their doctors better understand individual risk and make informed decisions about screening.
© $2026 Times Horizon Private Limited